LOS ANGELES, CA / ACCESSWIRE / October 24, 2017 / Stony Hill Corp. (OTC:STNY), a diversified company focused on the cannabis industry, founded by Damian Marley, announced it will expand its product line and launch a hemp-derived CBD product line under the Stony Hill CBD brand on Tuesday, October 24th. The products will be sold on Stony Hill's new website and in select locations in the U.S.
As the health and wellness market continues to more broadly accept the therapeutic properties and applications of hemp and cannabis, Stony Hill is working closely with doctors, scientists, industry advocates and the general public to ensure each group is receiving accurate, reliable and helpful information regarding the benefits of cannabis and our branded line of products.
Stony Hill's organic ingredients and formulations were created to target common ailments in the health and wellness industry for anyone who is open to trying hemp derived products. The products use industrial hemp as an input to produce high quality CBD for a variety of health and wellness products.
Chris Bridges, President of Stony Hill stated, "According to the Hemp Business Journal, the hemp-derived CBD products market is expected to surpass $450 million by 2020 and we are pleased to be getting involved during the industry's infancy. With the overall CBD market expected to surpass $2.1 billion by 2020, we feel strongly that the legalization and availability of hemp-based products stands to attract the lion's share of the market as cannabis-based CBD products overcome the federally imposed hurdles."
JJ Southard, Vice President of Products at Stony Hill Corp. added, "It is important for consumers to be educated on the differences between hemp-based CBD and cannabis for multiple reasons including efficacy, legality and safety. Hemp-derived CBDs provide an attractive alternative for people looking to reap the medical benefits of cannabis, but who cannot obtain cannabis due to legality issues, or simply do not want to experience the psychoactive effects of THC."
The new e-store, StonyHillCBD.com, currently offers Stony Hill's line of hemp-derived cannabidiol (CBD) isolate infused gummies, topicals and tinctures. Over time, Stony Hill will launch its product lines in specialty and retail stores.
The organic CBD gummies come in both daytime and nighttime formulations, with the additions of melatonin to facilitate healthy sleep cycles. The all-natural topical CBD lotions for pain and inflammation absorb quickly and are pleasantly scented with blood orange essential oil. The full-spectrum hemp-derived CBD tinctures come in a wide range of strengths to make dosing easier, and are offered in peppermint and flavorless varieties.
CBD is the non-psychoactive cannabinoid found in cannabis and hemp and has been used to treat a variety of medical conditions and ailments. CBD is a natural compound which functions naturally and seamlessly in the body. Cannabinoids are chemical compounds derived from cannabis and have shown the ability to stimulate the endocannabinoid system and provide therapeutic relief to many ailments.
About Stony Hill Corp.
Stony Hill Corp. (www.stonyhillcorp.com), founded by Damian Marley, is a diversified company focused on multiple areas of the cannabis, hemp and CBD industry. The company is focused on select investment, branding, real estate, and partnership opportunities in the recreational, health and wellness, nutraceutical, and media industries.
Stony Hill has several strategic partnerships and investments currently in place and is actively pursuing additional partnerships and strategic growth opportunities.
Except for historical information contained herein, statements in this release may be forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Stony Hill Corp. (the "Company") or its management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the Company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above and those risks discussed from time to time in the Company's filings with the Securities and Exchange Commission. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as (i) the development and protection of our brands and other intellectual property, (ii) the need to raise capital to meet business requirements, (iii) significant fluctuations in marketing expenses, (iv) the ability to achieve and expand significant levels of revenues, or recognize net income, from the sale of our products and services, (v) the Company's ability to conduct the business if there are changes in laws, regulations, or government policies related to cannabis, (vi) management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and (vii) other information that may be detailed from time to time in the Company's filings with the United States Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.